Labocanna SA
0.23
PLN
0.00
(0.00%)
Labocanna SA
GPW:LCN
(Warsaw Stock Exchange)
Recent
price
0.23
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Labocanna S.A., together with its subsidiaries, operates as a diversified commercial real estate management and hemp industry enterprise based in Poland. The company operates through two primary business segments: Commercial Real Estate and Hemp & Cannabis Products. Its core product and service portfolio comprises commercial property leasing, retail space rental, and tenant administration centered on the FoxPark shopping center in Koszalin; distribution and commercialization of hemp-derived consumer health formulations, including Labocanna-branded cannabidiol (CBD) oils, botanical extracts, and dietary supplements; manufacturing and sale of natural hemp cosmetics, skincare products, and personal care preparations through its subsidiary CannaBio Sp. z o.o.; research, development, and application studies on industrial hemp fibers for cosmetics, bioplastics, and textiles; and project development for indoor medical cannabis cultivation and processing infrastructure. Headquartered in Koszalin, Poland, Labocanna S.A. was incorporated in 2011 and was formerly known as Call Center Tools S.A. and Foxbuy.com S.A. before rebranding to Labocanna S.A. to mark its strategic focus on the Central and Eastern European hemp market. In recent operational and corporate developments, the company acquired the underlying land property for its flagship FoxPark commercial center to consolidate its primary cash-generating asset, secured multi-million zloty debt financing and capital increases to fund ongoing working capital and infrastructure projects, and restructured its venture holdings by realigning investments in medical cannabis entities to prioritize core property cash flows alongside targeted hemp commercialization.